Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy

[1]  K. Hanna.  Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[2]  M. Kyrtsonis,et al.  Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece , 2019, Leukemia & lymphoma.

[3]  J. Byrd,et al.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[4]  M. Pulsipher,et al.  Hypogammaglobulinemia due to CAR T-cell therapy , 2017, Pediatric blood & cancer.

[5]  R. Foà,et al.  Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. , 2017, Leukemia research.

[6]  P. Feugier,et al.  Real‐world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients , 2017, American journal of hematology.

[7]  A. Österborg,et al.  Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group , 2016, Haematologica.

[8]  E. Kimby,et al.  Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion , 2016, Expert review of clinical immunology.

[9]  L. Sehn,et al.  A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia. , 2016, Current oncology.

[10]  G. Marti,et al.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. , 2015, Blood.

[11]  Deborah A. Bowen,et al.  Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes , 2015, Cancer.

[12]  E. Montserrat,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Berrebi,et al.  Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group , 2014, European Journal of Haematology.

[14]  Smita Y. Patel,et al.  Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin? , 2014, Journal of Clinical Immunology.

[15]  G. d’Ettorre,et al.  Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) , 2014, Scandinavian journal of infectious diseases.

[16]  Jeffrey A Jones,et al.  Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. , 2014, The Lancet. Oncology.

[17]  Juthamas Sukbuntherng,et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.

[18]  O. G. Best,et al.  Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia , 2013, Leukemia & lymphoma.

[19]  M. Leandro,et al.  Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. , 2012, Rheumatology.

[20]  S. Kaveri,et al.  Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy , 2011, Clinical and experimental immunology.

[21]  M. Hallek,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  T. Hamblin,et al.  The immunodeficiency of chronic lymphocytic leukaemia. , 2008, British medical bulletin.

[23]  L. Honigberg,et al.  Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase , 2007, ChemMedChem.

[24]  P. Laippala,et al.  Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia. , 1999, Leukemia & lymphoma.

[25]  N. Jackson,et al.  Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. , 2008, Clinical and laboratory haematology.

[26]  M P Lawton,et al.  Validation of the Cumulative Illness Rating Scale in a Geriatric Residential Population , 1995, Journal of the American Geriatrics Society.

[27]  F. Ries,et al.  Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes , 1994, British journal of haematology.

[28]  H. Chapel,et al.  Predictors of infection in chronic lymphocytic leukaemia (CLL) , 1992, Clinical and experimental immunology.

[29]  E. Montserrat,et al.  Serum immunoglobulins in B‐chronic lymphocytic leukemia. Natural history and prognostic significance , 1988, Cancer.

[30]  J. R. Smith,et al.  Serum immunoglobulins and lymphocyte subsets in chronic lymphocytic leukemia. , 1987, American journal of clinical pathology.

[31]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.